Altoida

Enabling Early Detection for a Healthier Brain

Revolutionizing neurology diagnostics with our digital NeuroMarker Platform designed to rapidly detect early cognitive decline and empower healthcare providers to intervene sooner—when treatment is most effective.
Learn more about our platform

Current Diagnostics Miss Early Detection

Leading to Long Wait Times for Treatment Decisions

2,000

People per day progress to more advanced stages of Alzheimer’s disease.

20

U.S. states are “dementia neurology deserts” as shrinking provider networks and rising demand have created a critical neurologist shortage, labeled a “grave threat” by the American Academy of Neurology.

70+

Months a patient will wait from cognitive complaint to a treatment decision with current standard care by 2033. The current wait is 12 months.
Early detection of mild cognitive impairment (MCI) and Alzheimer’s is often delayed due to limited access to specialized diagnostics, leaving some patients waiting years for a diagnosis. Current standard of care, paper-based cognitive assessments can be subjective, misdiagnose up to 30% of cases and fail to capture subtle cognitive and functional changes, further delaying treatment decisions and hindering early intervention.  These challenges lead to significant delays in care, increasing the burden on patients, caregivers, and already overextended healthcare providers.

Advancing Early Detection for

Faster, More Effective Intervention

The aim of Altoida’s groundbreaking NeuroMarker Platform is to empower clinicians with real-time insights during a single office visit. Using machine learning and augmented reality to simulate instrumental activities of daily living (iADL), it is designed to detect the earliest signs of cognitive impairment. Developed for faster diagnosis, this platform is intended to help healthcare providers intervene sooner, giving millions of patients a better chance at receiving timely, effective treatment.

Discover our Platform

Pioneering

Early Detection in Cognitive Health

The Altoida NeuroMarker Platform — built on two decades of peer-reviewed research, scientific validation, and evidence generation — is designed to detect mild cognitive impairment (MCI) and early signs of Alzheimer’s disease in just 10 minutes. Trusted by leading global pharmaceutical companies and validated in numerous independent clinical studies, the platform aims to empower earlier diagnosis, accelerates clinical trials, and enhance patient care and outcomes.

Read our Latest Breakthroughs

Proven: Early & Accurate Detection of Prodromal Alzheimer's Disease

The Altoida NeuroMarker Platform can effectively identify preclinical and prodromal Alzheimer's disease quicker than traditional neuropsychological tests without any learning effects.
Read the RADAR-AD Study

The Vital Role of Diagnostics in

Advancing Alzheimer's Research

Explore recent studies that highlight how innovative diagnostics are driving breakthroughs in Alzheimer's diagnosis and treatment.

1 2 3 4 5 6 … 51
More Resources

News

Shaping the Future of Cognitive Health

The latest coverage on our work. Explore how Altoida’s technology is shaping the future of early detection and transforming patient care.
1 2 3 4 5 6
View all News

Get in Touch with Us

Whether you have questions about our platform or want to explore partnership opportunities, we’re here to help. Our team is ready to provide you with the answers and support you need.